The absence of apoeccrine glands in the human axilla has disease pathogenetic implications, including axillary hyperhidrosis

School of Life Sciences, Glasgow Caledonian University, Glasgow, UK.
British Journal of Dermatology (Impact Factor: 4.28). 07/2007; 156(6):1278-86. DOI: 10.1111/j.1365-2133.2007.07917.x
Source: PubMed


The existence of a third type of sweat gland in human axillary skin, the apoeccrine gland, with a capacity to produce much higher sweat output than the eccrine gland, was proposed from examination of microdissected glands. However, previous studies of axillary skin glands did not examine the entire individual glandular structure via serial sections and the markers used to identify the different glands gave conflicting results and, hence, the existence of the apoeccrine gland remains controversial.
To investigate human axillary sweat glands by serial section histology and immunofluorescence.
Human axillary sweat glands were investigated by serial sectioning of paraffin wax-embedded skin samples taken by biopsy from four male and six female volunteers (age range 20-35 years). Sections were examined by light microscopy and immunofluorescence, using antibodies to antigens reported to be markers for discriminating between eccrine and apocrine gland cells: CD15, CD44, S100 and human milk fat globulin.
Light microscopy demonstrated that there were hair follicles and a mean +/- SD of 76 +/- 14 sweat glands cm(-2). Eccrine and apocrine glands were found to be present; however, no glands resembling the apoeccrine glands were detected. Both types of sweat gland exhibited signs of being active, with segments of the secretory coils displaying flattened cells and dilated glandular lumina; however, this dilation did not extend to obvious changes in the width of the gland. None of the eccrine glands exhibited evidence of the presence of apocrine cells or vice versa. Immunofluorescence markers were found not to be specific and did not discriminate between the different types of glands or demonstrate the presence of apoeccrine glands.
This is the first time that serial sections of axillary skin have been examined by histology and immunofluorescence. The markers reported to discriminate between apocrine and eccrine glands were found to be nonspecific. No evidence of apoeccrine glands was found either by histology or by immunofluorescence.

Download full-text


Available from: Mark Harker,
  • Source

    International journal of cosmetic science 01/2008; 30(1):69 - 71. DOI:10.1111/j.1468-2494.2008.00413.x · 1.38 Impact Factor

  • International journal of cosmetic science 03/2008; 30(1):67-8; author reply 69-71. DOI:10.1111/j.1468-2494.2008.00412.x · 1.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: HH is a chronic disease that can have a significant negative impact on a patient's quality of life. Primarily involving the axillae, palms, soles, and face, patients who have primary focal HH seek medical advice often long after they have been living with functional and psychosocial disability for some time. For every affected area of HH and at every stage of disease severity, conservative measures should be exhausted before progressing to surgical options. Treatment should be particular to each individual patient and chosen based on disease severity, expectations for improvement, and disease location. Generally, the most conservative options with the fewest adverse effects are attempted first. These include topical therapy (primarily AlCl3-6H2O) and iontophoresis. Patients who are less likely to respond to these measures are those living with severe disease (HDSS score of three or four). A minimally invasive procedure, intradermal BTX injections have been shown to improve disease significantly in these patients. Serving as an intermediate between conservative therapy and invasive surgery, BTX has revolutionized the treatment of focal HH. In many large controlled studies, it has been proved to be safe, efficacious, quick acting, and long lasting. Although BTX-A is most commonly used and studied, preliminary studies of BTX-B have demonstrated its potential to ameliorate focal HH significantly. Oral medications such as glycopyrrolate can be tried alone at any point in treatment, or as a useful adjunct, but side effects are common and caution should be taken with high-risk patients. For all forms of HH, the desired outcome for treatment should be qualitative and quantitative and it is critical for physicians to assess the patient's improvement periodically and adjust therapy, based on these therapeutic landmarks.
    Thoracic Surgery Clinics 06/2008; 18(2):141-55. DOI:10.1016/j.thorsurg.2008.01.003 · 0.77 Impact Factor
Show more